Nuclidium has secured $98 million (84 million euros) in Series B funding.
The company plans to use the funding to advance clinical development of its copper-61 (Cu-61)/copper-67 (Cu-67) theranostic pipeline across multiple oncology indications, it said.
The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, Nuclidium said.
